Luciana Borio, serving as a director at Insulet Corp (NASDAQ:PODD), completed a sale of 418 shares of common stock on June 3, 2026. The transaction was executed at a price of $143.27 per share, totaling approximately $59,886. Following this sale, Ms. Borio directly holds 4,329 shares of Insulet Corp common stock. The transaction was reported on June 4, 2026.
The insider sale comes as Insulet shares trade near their 52-week low of $140.63, down roughly 55% over the past year. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value suggesting significant upside potential. The company maintains a market cap of $10.2 billion and trades at a P/E ratio of 34.3.
In other recent news, Insulet Corporation announced the U.S. rollout of enhancements to its Omnipod 5 Automated Insulin Delivery System. These updates, which received FDA clearance in December 2025, include a new 100 mg/dL target glucose option, expanding the available settings. Real-world data showed significant improvements in median time in range for users with both type 1 and type 2 diabetes when transitioning to lower glucose targets.
Additionally, Insulet issued a voluntary medical device correction affecting approximately 7 million Omnipod insulin pods due to a manufacturing defect that could cause insulin under-delivery. This recall involves specific lots of Omnipod 5, Omnipod DASH, and Omnipod Eros pods. Despite this recall, Benchmark maintained a Buy rating on Insulet with a $250.00 price target. William Blair also initiated coverage with an Outperform rating, noting the stock’s valuation compared to peers despite faster sales growth.
These developments highlight recent changes and challenges for Insulet Corporation.